GENinCode’s mission as a clinical-genetic diagnostic company is to apply a combination of polygenics, a proprietary bioinformatics platform and AI to risk-assess and prevent cardiovascular disease. The company set a UK precedent in being the first to have a CVD commercial polygenic test implemented in the NHS and keenly awaits another milestone, US 510k clearance in 2024.
Ten years ago, few scientific papers were being issued on polygenics, a branch of science that assesses an individual’s genetic variants to predict the heritable risk of developing a particular disease over their lifetime.
This year, it is estimated that over 2,000 international studies will be published, said Matthew Walls, CEO of UK AIM-listed...